Leonardo Riella (US)

Chair Presenter

Medical Director of Kidney Transplantation · Massachusetts General Hospital, Harvard Medical School · Boston

Leonardo Riella
Biography Click to expand

Leonardo V. Riella, MD, PhD is the Harold and Ellen Danser Endowed Chair in Transplant Surgery and Associate Professor of Surgery and Medicine at Harvard Medical School. He serves as Medical Director of Kidney Transplantation at Massachusetts General Hospital, where he leads clinical and research efforts to advance the field of transplantation. Dr. Riella’s work focuses on immune regulation, transplant tolerance, and the development of innovative therapies to improve long term transplant outcomes. He founded and leads the TANGO Consortium, the largest international collaborative network dedicated to studying recurrence of glomerular diseases after kidney transplantation. In March 2024, Dr. Riella led the world’s first successful transplantation of a gene edited pig kidney into a living human, a landmark achievement that has accelerated the clinical translation of xenotransplantation. His work combines clinical innovation with advanced immune profiling approaches to better understand and modulate the immune response in transplantation.

The Inaugural Richard Slayman International Workshop on Xenotransplantation Click to watch
Leonardo Riella (Guest Speaker)
In this Behind the Paper episode, Macey Levan, MD and Leonardo V. Riella, MD discuss the key insights from:

📄 Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation
Meeting Report – Published in Transplantation (February 2026)

This landmark workshop brought together more than 140 participants from North America, Europe, and Asia to examine the latest advances—and the remaining challenges—in translating xenotransplantation from bench to bedside.

Framed by the legacy of Richard Slayman, the first living recipient of a genetically edited pig kidney, this conversation explores how patient courage, scientific collaboration, and careful clinical design are helping move the field from possibility toward reality.

The episode highlights:

🔹 Why patient selection is critical in early xenotransplantation trials
🔹 How genetic editing is helping overcome immune incompatibility
🔹 The evolving role of immunosuppression, including complement inhibition and CD154 blockade
🔹 New molecular tools for immune and infectious surveillance
🔹 The importance of transparency, ethics, and global collaboration
🔹 What the next 5–10 years may look like for kidney xenotransplantation

This discussion offers an important look at one of the most promising and complex frontiers in transplantation—where innovation, safety, and patient-centered care must advance together.

Programme roles

Sunday, September 20, 2026

Darling Harbour
Presenter Plenary Session
Plenary Session 1
Lecture Early clinical experience with gene-edited porcine kidney xenotransplantation in four living human recipients

Tuesday, September 22, 2026